Development of Novel, Biophysically Designed Fluids for Swallowing Disorders

NCT ID: NCT03131869

Last Updated: 2017-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-22

Study Completion Date

2018-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People suffering from swallowing disorders (dysphagia) have a hard time swallowing liquids that are too thin (like water or coffee) or too thick, correctly. They can have health problems, such as chest infections and malnutrition because when they try to drink, some of the liquid "goes down the wrong pipe" and into the lungs. To help people with dysphagia, Swallow Solutions is developing thickened liquids that have added nutrition, taste good, and quench thirst, but are still easy and safe to swallow.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A. Background Dysphagia, a devastating swallowing disorder affecting more than 18M adults and millions more children in the U.S. \[1,2\], is associated with increased mortality and morbidity, including malnutrition, dehydration, pulmonary complications, and reduced quality of life \[3,4\]. Dysphagia often causes thin liquids (e.g., water, coffee) to be aspirated or misdirected into the pulmonary-rather than to the digestive-system during swallowing, significantly increasing the risk of aspiration pneumonia \[5,6\]. Radiographic methods used in \>80% of U.S. hospitals to diagnose dysphagia involve standardized fluids with specific rheological characteristics (e.g., apparent viscosity, flow properties) \[7\]. Thickened beverages are the most commonly recommended intervention after dysphagia diagnosis \[8\]. Perplexingly, currently available dietary beverages differ from the rheological characteristics of standardized diagnostic fluids, causing a critical disconnect between diagnosis and treatment \[9\]. A rheologic study of commercially available thickened beverages and diagnostic fluids found that some commercial nectar products, while approaching the target apparent viscosity (n ) for the diagnostic standard (VaribarĀ® Nectar, n 30=300 cP), differed in other rheological parameters such as flow index (n), consistency (K), and yield stress. o commercial thin-honey consistency products matched the diagnostic standard for any of these rheological parameters. This disconnect frequently causes the bolus to flow toward the airway, increasing the risk of negative health sequelae.

Swallow Solutions, LLC will build on the successful completion of our Phase I project to continue to bridge the gap between clinical need and existing products. Based on insights from our Phase I results, investigators will develop a complete product line (tentatively branded as SwallowSAFE Thickened Beverages) to meet the unique-currently unmet-needs of dysphagic patients. This novel thickened beverage line will provide hydration and nutrition, thus circumventing potentially life-threatening and costly health problems associated with dysphagia. The investigators propose to accomplish the following specific aims.

Specific Aims

Aim 1. Complete a full complement of prototype ready-to-drink, thickened, and nutritionally-enhanced medical liquids that are shelf-stable and appealing, with pre-determined rheological and nutritional properties. T

Aim 2. Demonstrate improved patient safety resulting from novel, biophysically designed thickened beverages (full product line) compared to currently available thickened beverage options.

Aim 3. Develop production for the full SwallowSAFE product line of ready-to-drink, thickened beverages (with and without nutritional enrichment) at 2 target viscosities (nectar and thin-honey) in 1-3 flavors each.

B. Study Design: Clinical Research (Aim 2)

Dysphagic patients (n=200) will swallow prototype beverages (with 10% added barium) and also thickened beverages that are currently on the market (with 10% added barium) during a videofluoroscopic (radiographic) evaluation of swallowing that is part of their standard clinical care. The investigators will use established, quantified, objective safety measures of a) airway invasion (Penetration/Aspiration Scale) \[13,14\] and b) oropharyngeal residue \[15\]. Potential subjects will be adults (age \>55 years) with suspected dysphagia based on referral for the diagnostic evaluation. The study will include patients with a variety of medical etiologies to allow for greater generalizability of results. Each consenting subject will complete a videofluoroscopic swallowing assessment lasting \~45 min per standard clinical care. Data will be collected from 200 subjects from two large acute-care hospitals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deglutition Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thickened Beverages Nectar

Thickened beverages in nectar consistency

Intervention Type OTHER

Thickened Beverage Honey

Thickened beverages in honey consistency

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 55 years of age or older
* physician approval of medical stability
* aspiration or penetration of the laryngeal vestibule (score of 3 or higher on the Penetration/Aspiration Scale) or post-swallow residue in the oropharynx as instrumentally documented by a Speech-Language Pathologist (SLP) during a standard videofluoroscopic oropharyngeal swallow study
* capacity to provide informed consent.

Exclusion Criteria

* poorly controlled psychosis (3 or more related hospitalizations in one year
* refractory alcoholism (on AWD precautions)
* allergy to barium (used in radiographic swallowing assessment)
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Nursing Research (NINR)

NIH

Sponsor Role collaborator

Swallow Solutions

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Horler, MBA

Role: PRINCIPAL_INVESTIGATOR

Swallow Solutions

JoAnne Robbins, PhD

Role: PRINCIPAL_INVESTIGATOR

Swallow Solutions

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Meriter Hospital

Madison, Wisconsin, United States

Site Status RECRUITING

Marshfield Clinic

Marshfield, Wisconsin, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jackie Hind, MS

Role: CONTACT

Phone: 608-238-6678

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sharon Bair, MS

Role: primary

Lisa Bast, MS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2R44NR015193-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2R44NR015193-02

Identifier Type: NIH

Identifier Source: org_study_id

View Link